[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.240.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,073
Citations 0
Original Investigation
January 2, 2020

Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder: Secondary Analysis of a Randomized Clinical Trial

Author Affiliations
  • 1Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California
  • 2Wu Tsai Neuroscience Institute, Stanford University, Stanford, California
  • 3Veterans Affairs Palo Alto Healthcare System, Palo Alto, California
  • 4Sierra Pacific Mental Illness, Research, Education, and Clinical Center, Palo Alto, California
  • 5Department of Psychiatry, Dell Medical School, The University of Texas at Austin
  • 6School of Automation Science and Engineering, South China University of Technology, Guangzhou, Guangdong, China
  • 7Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas
  • 8Department of Psychiatry, Harvard Medical School, Boston, Massachusetts
  • 9New York State Psychiatric Institute, Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York
  • 10now at Alto Neuroscience Inc, Los Altos, California
JAMA Psychiatry. Published online January 2, 2020. doi:10.1001/jamapsychiatry.2019.3867
Key Points

Question  What electroencephalographic connectivity features are neural moderators of antidepressant treatment response?

Findings  In this secondary analysis of a randomized clinical trial, greater alpha-band and lower gamma-band connectivity—most prominently parietal—predicted better placebo treatment response and worse antidepressant treatment response. Lower connectivity levels in these moderating connections were associated with higher levels of anhedonia.

Meaning  Key cortical features differentiating placebo response from antidepressant response were identified, providing an alternative direction toward establishing a placebo signature in clinical trials.

Abstract

Importance  Despite the widespread awareness of functional magnetic resonance imaging findings suggesting a role for cortical connectivity networks in treatment selection for major depressive disorder, its clinical utility remains limited. Recent methodological advances have revealed functional magnetic resonance imaging–like connectivity networks using electroencephalography (EEG), a tool more easily implemented in clinical practice.

Objective  To determine whether EEG connectivity could reveal neural moderators of antidepressant treatment.

Design, Setting, and Participants  In this nonprespecified secondary analysis, data were analyzed from the Establishing Moderators and Biosignatures of Antidepressant Response in Clinic Care study, a placebo-controlled, double-blinded randomized clinical trial. Recruitment began July 29, 2011, and was completed December 15, 2015. A random sample of 221 outpatients with depression aged 18 to 65 years who were not taking medication for depression was recruited and assessed at 4 clinical sites. Analysis was performed on an intent-to-treat basis. Statistical analysis was performed from November 16, 2018, to May 23, 2019.

Interventions  Patients received either the selective serotonin reuptake inhibitor sertraline hydrochloride or placebo for 8 weeks.

Main Outcomes and Measures  Electroencephalographic orthogonalized power envelope connectivity analyses were applied to resting-state EEG data. Intent-to-treat prediction linear mixed models were used to determine which pretreatment connectivity patterns were associated with response to sertraline vs placebo. The primary clinical outcome was the total score on the 17-item Hamilton Rating Scale for Depression, administered at each study visit.

Results  Of the participants recruited, 9 withdrew after first dose owing to reported adverse effects, and 221 participants (150 women; mean [SD] age, 37.8 [12.7] years) underwent EEG recordings and had high-quality pretreatment EEG data. After correction for multiple comparisons, connectome-wide analyses revealed moderation by connections within and between widespread cortical regions—most prominently parietal—for both the antidepressant and placebo groups. Greater alpha-band and lower gamma-band connectivity predicted better placebo outcomes and worse antidepressant outcomes. Lower connectivity levels in these moderating connections were associated with higher levels of anhedonia. Connectivity features that moderate treatment response differentially by treatment group were distinct from connectivity features that change from baseline to 1 week into treatment. The group mean (SD) score on the 17-item Hamilton Rating Scale for Depression was 18.35 (4.58) at baseline and 26.14 (30.37) across all time points.

Conclusions and Relevance  These findings establish the utility of EEG-based network functional connectivity analyses for differentiating between responses to an antidepressant vs placebo. A role emerged for parietal cortical regions in predicting placebo outcome. From a treatment perspective, capitalizing on the therapeutic components leading to placebo response differentially from antidepressant response should provide an alternative direction toward establishing a placebo signature in clinical trials, thereby enhancing the signal detection in randomized clinical trials.

Trial Registration  ClinicalTrials.gov identifier: NCT01407094

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×